Physician profile
Todd Hellmich
NPI 1841713922
$4,443.35
in general payments reported to CMS, 2019-2025
12 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 90% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $354 · 2023: $1,257 · 2024: $1,388 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,066 · Education: $22.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,066.35 |
| Education | $22.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $691.67 | 2022-2025 | Epclusa, Veklury |
| Melinta Therapeutics, LLC | $639.47 | 2022-2025 | Kimyrsa, Rezzayo, Vabomere |
| Merck Sharp & Dohme LLC | $564.33 | 2022-2025 | Pifeltro, Dificid, Delstrigo |
| Shionogi INC | $527.89 | 2022-2025 | Fetroja |
| Abbvie INC. | $478.24 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $461.93 | 2022-2025 | Nuzyra |
| Viiv Healthcare Company | $331.94 | 2023-2025 | Dovato, Cabenuva |
| Aimmune Therapeutics, INC. | $219.00 | 2024-2025 | Vowst |
| La Jolla Pharmaceutical Company | $185.43 | 2022-2025 | Xerava, Zevtera |
| Insmed, INC. | $181.29 | 2023-2025 | Arikayce |
| Ferring Pharmaceuticals INC. | $119.72 | 2023-2025 | Rebyota |
| Tetraphase Pharmaceuticals, INC. | $42.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Hellmich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.